Upon joining the study, you will be required to provide informed consent. This means you agree to participate after understanding the details and potential risks of the study.

You will need to confirm that you require urgent surgery or a procedure and that you have been taking a medication known as a factor Xa inhibitor (such as apixaban, rivaroxaban, or edoxaban) within the last 15 hours.

A screening process will be conducted to ensure you meet the study’s criteria. This includes confirming the need for urgent surgery or procedure and the use of a factor Xa inhibitor.

Female participants of childbearing potential will undergo a pregnancy test to ensure eligibility.

If eligible, you will receive a treatment called andexanet alfa or usual care. Andexanet alfa is administered through an intravenous infusion, which means it is given directly into a vein.

The goal of the treatment is to help control bleeding during your surgery or procedure.

You will undergo the planned urgent surgery or procedure. The medical team will monitor your condition closely to ensure effective control of bleeding.

After the surgery or procedure, your recovery will be monitored. This includes checking the effectiveness of the treatment in controlling bleeding.

Your anti-FXa activity levels, which indicate the effect of the factor Xa inhibitor, will be measured at the start of the surgery and two hours after the surgery begins.

You will have follow-up visits to assess your recovery and any potential side effects from the treatment.

These visits are important to ensure your safety and the effectiveness of the treatment you received.